RLY-8161 / Relay Therap - LARVOL DELTA

Initiated Phase 1/2 clinical trial for RLY-8161, a NRAS-selective inhibitor, in patients with NRAS-mutant melanoma and other NRAS-mutant solid tumors (GlobeNewswire)

Trial status • Melanoma • Solid Tumor

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors (clinicaltrials.gov) - P1 | N=35 | Recruiting | Sponsor: Relay Therapeutics, Inc.

First-in-human • New P1 trial • Melanoma • Oncology • Solid Tumor • NRAS

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire) - "Anticipated Upcoming Milestones: (i) Breast Cancer: RLY-2608 + fulvestrant data update in the fourth quarter of 2024; RLY-2608 + fulvestrant + ribociclib initial safety data in the fourth quarter of 2024; RLY-2608 + fulvestrant + atirmociclib clinical trial initiation by the end of 2024; RLY-2608 + fulvestrant potential Phase 3 trial initiation in 2025; (ii) Lirafugratinib: tumor agnostic data and regulatory update in the second half of 2024; (iii) Pre-clinical:...NRAS: clinical start in the second half of 2025."

New P3 trial • New trial • P1 data • Regulatory • Breast Cancer • Cholangiocarcinoma

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event (GlobeNewswire) - "Relay Therapeutics...will provide details on the company’s portfolio during its New Program & Platform event today, June 6, 2024, from 8:00 to 10:00 a.m. ET...The new programs include two novel programs from its genetic disease portfolio and a potentially first-in-class NRAS-selective inhibitor...Relay Therapeutics has created the first NRAS-selective inhibitor...The company expects to initiate clinical development of its NRAS-selective inhibitor in the second half of 2025...Anticipated Milestones....RLY-2608 + fulvestrant potential Phase 3 trial initiation in 2025."

New molecule • New P3 trial • Breast Cancer • Oncology • Solid Tumor